Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 373

1.

Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients.

Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R.

Clin Rheumatol. 2007 Nov;26(11):1969-71. Epub 2007 Mar 6.

PMID:
17340045
2.

Tumor necrosis factor-alpha antagonist-induced sarcoidosis.

Clementine RR, Lyman J, Zakem J, Mallepalli J, Lindsey S, Quinet R.

J Clin Rheumatol. 2010 Sep;16(6):274-9. doi: 10.1097/RHU.0b013e3181efa190.

PMID:
20808167
3.

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.

Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN Jr, Braun MM.

Arthritis Rheum. 2002 Oct;46(10):2565-70.

4.

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group..

Arthritis Rheum. 2003 Aug;48(8):2122-7.

5.

Development of sarcoidosis 6-month post discontinuation of etanercept: coincidence or real association?

Haroon M, Ryan JG, Harney S.

Clin Rheumatol. 2011 Aug;30(8):1095-8. doi: 10.1007/s10067-011-1704-7. Epub 2011 Mar 8.

PMID:
21380931
6.

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.

De Bandt M, Sibilia J, Le Loët X, Prouzeau S, Fautrel B, Marcelli C, Boucquillard E, Siame JL, Mariette X; Club Rhumatismes et Inflammation..

Arthritis Res Ther. 2005;7(3):R545-51. Epub 2005 Mar 1.

7.

Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis.

Laas K, Peltomaa R, Kautiainen H, Leirisalo-Repo M.

Clin Rheumatol. 2008 Jul;27(7):927-32. doi: 10.1007/s10067-008-0880-6. Epub 2008 Apr 15.

PMID:
18414967
8.

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.

Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM.

Arthritis Rheum. 2003 Feb;48(2):319-24.

9.

The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.

Hansen KE, Hildebrand JP, Genovese MC, Cush JJ, Patel S, Cooley DA, Cohen SB, Gangnon RE, Schiff MH.

J Rheumatol. 2004 Jun;31(6):1098-102.

PMID:
15170921
10.

Uveitis associated with sarcoidosis exacerbated by etanercept therapy.

Suzuki J, Goto H.

Jpn J Ophthalmol. 2009 Jul;53(4):439-40. doi: 10.1007/s10384-009-0691-6. Epub 2009 Sep 8. No abstract available.

PMID:
19763766
11.

Development of sarcoidosis following etanercept treatment: a report of three cases.

Skoie IM, Wildhagen K, Omdal R.

Rheumatol Int. 2012 Apr;32(4):1049-53. doi: 10.1007/s00296-009-1349-x. Epub 2010 Jan 9.

PMID:
20062997
12.

Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.

Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, Kim TH, Jun JB, Yoo DH, Lee JT, Bae SC.

J Rheumatol. 2007 Apr;34(4):706-11. Epub 2007 Feb 15.

PMID:
17309133
13.

Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series.

Toussirot E, Berthelot JM, Pertuiset E, Bouvard B, Gaudin P, Wendling D, le Noach J, Lohse A, Lecuyer E, Cri L.

J Rheumatol. 2009 Nov;36(11):2421-7. doi: 10.3899/jrheum.090030. Epub 2009 Oct 1.

PMID:
19797509
14.

Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.

Exarchou SA, Voulgari PV, Markatseli TE, Zioga A, Drosos AA.

Scand J Rheumatol. 2009;38(5):328-31. doi: 10.1080/03009740902922612.

PMID:
19579151
15.

Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.

Gilaberte Y, Coscojuela C, Vázquez C, Roselló R, Vera J.

Br J Dermatol. 2007 Feb;156(2):368-71. Review.

PMID:
17223880
16.

[Membranous nephropathy secondary to rheumatoid arthritis occurring during anti-TNFalpha therapy and responsive to second-line treatment with rituximab].

Giordano A, Cencioni L, Salvo DP, Berrettini M.

G Ital Nefrol. 2011 Mar-Apr;28(2):214-8. Italian.

PMID:
21488037
17.

Anti-TNF-alpha-induced systemic lupus syndrome.

Debandt M, Vittecoq O, Descamps V, Le Loët X, Meyer O.

Clin Rheumatol. 2003 Feb;22(1):56-61.

PMID:
12605321
18.
20.

Adenoviral pneumonia during etanercept treatment in a patient with rheumatoid arthritis.

Kang MJ, Kim MS, Choi EH, Lee KE, Kim YK, Choi HJ.

Korean J Intern Med. 2007 Mar;22(1):63-6.

Supplemental Content

Support Center